Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.

Update to Johnson & Johnson PFA platform gains FDA approval
The Varipulse PFA platform originally gained FDA approval in 2024. According to Johnson & Johnson MedTech, this update was put in place to help the technology provide better patient outcomes going forward.
FDA approves Bayer's finerenone to treat wide range of heart failure patients
Finerenone, sold by Bayer under the brand name Kerendia, is now approved in the United States for the treatment of HFmrEF and HFpEF. The drug has already been used for years to treat patients with chronic kidney disease and type 2 diabetes.
FDA details multiple Class I recalls for Edwards Lifesciences surgical devices
Edwards Lifesciences has recalled more than 61,000 medical devices due to the risk of a small piece of wire becoming exposed. No patient injuries have been reported at this time.
CMS proposes Medicare coverage for renal denervation
This proposal, if finalized, would dramatically increase patient access to renal denervation. Both Recor Medical and Medtronic have shared their excitement over the news.
ASE shares new recommendations for evaluating LV diastolic function, HFpEF
The new guidelines detail the use of echocardiography to evaluate patients for a variety of conditions.

What older patients are getting wrong about statins and aspirin—and how cardiologists can help

A new analysis in the Journal of the American Geriatrics Society suggests physicians could be doing more to help older patients combat cardiovascular disease.

A month after discharge, heart damage still present in 54% of COVID-19 patients with raised troponin levels

“Importantly, the pattern of damage to the heart was variable, suggesting that the heart is at risk of different types of injury,” one researcher said.

Living an active lifestyle reduces chances of dying immediately after a heart attack

The study, published in the European Journal of Preventive Cardiology, included data from more than 28,000 patients.

FDA approves expanded indication for sacubitril/valsartan

Manufactured by Novartis under the name Entresto, the medication is now also approved for treating HFpEF.

Healthcare for children heavily delayed during the pandemic

A significant proportion of parents delayed or put off healthcare visits and care for their children during the Covid-19 pandemic, according to a new report from the Urban Institute and the Robert Wood Johnson Foundation.

coronavirus COVID-19 vaccine vaccination

AI algorithm targets new coronavirus outbreaks

Researchers are using AI to predict which mammals are hosts of new coronavirus diseases, potentially identifying and predicting new outbreaks before they become deadly in the future.

Heart failure medication may offer relief for patients with COVID-related POTS

Overall, researchers found that ivabradine was a “safe and effective” POTS treatment associated with making significant improvements to patient heart rates and quality of life.

AI spots dozens of missed incidental pulmonary embolism diagnoses at one hospital

The investigation was retrospective, but Duke scientists believe their algorithm could potentially aid radiologists in spotting near-misses in their work.

Clinical

Update to Johnson & Johnson PFA platform gains FDA approval

FDA approves Bayer's finerenone to treat wide range of heart failure patients

FDA details multiple Class I recalls for Edwards Lifesciences surgical devices

CMS proposes Medicare coverage for renal denervation

ASE shares new recommendations for evaluating LV diastolic function, HFpEF